These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 2491972)
1. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. Clozel JP; Tschopp T; Luedin E; Holvoet P Circulation; 1989 Jan; 79(1):125-33. PubMed ID: 2491972 [TBL] [Abstract][Full Text] [Related]
2. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Collen D; Stassen JM; De Cock F Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288 [TBL] [Abstract][Full Text] [Related]
3. SSR182289A enhances thrombolysis induced by fibrinolytic agents in rabbit models of venous and arterial thrombosis. Visconte C; Sainte-Marie M; Lorrain J; Millet L; O'Connor SE; Schaeffer P; Herbert JM J Thromb Haemost; 2004 Apr; 2(4):629-36. PubMed ID: 15102019 [TBL] [Abstract][Full Text] [Related]
4. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138 [TBL] [Abstract][Full Text] [Related]
5. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080 [TBL] [Abstract][Full Text] [Related]
6. Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model. Guerrero B; Arocha-Piñango CL; Pinto MA; Müller CA; Gil San Juan AG; Amorim S; Perales J Blood Coagul Fibrinolysis; 2001 Oct; 12(7):521-9. PubMed ID: 11685039 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli. Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000 [TBL] [Abstract][Full Text] [Related]
8. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052 [TBL] [Abstract][Full Text] [Related]
9. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. Collen D; Stassen JM; Verstraete M J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615 [TBL] [Abstract][Full Text] [Related]
10. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220 [TBL] [Abstract][Full Text] [Related]
11. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains. Emeis JJ; Verheijen JH Arzneimittelforschung; 1992 Mar; 42(3):358-62. PubMed ID: 1497699 [TBL] [Abstract][Full Text] [Related]
12. Small animal thrombosis models for the evaluation of thrombolytic agents. Stassen JM; Lijnen HR; Kieckens L; Collen D Circulation; 1991 Jun; 83(6 Suppl):IV65-72. PubMed ID: 2040073 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Collen D; Stassen JM; Larsen G Blood; 1988 Jan; 71(1):216-9. PubMed ID: 3120823 [TBL] [Abstract][Full Text] [Related]
14. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535 [TBL] [Abstract][Full Text] [Related]
15. The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. Agnelli G; Buchanan MR; Fernandez F; Hirsh J Thromb Res; 1985 Dec; 40(6):769-77. PubMed ID: 3937287 [TBL] [Abstract][Full Text] [Related]
16. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. Larsen GR; Timony GA; Horgan PG; Barone KM; Henson KS; Angus LB; Stoudemire JB J Biol Chem; 1991 May; 266(13):8156-61. PubMed ID: 1708773 [TBL] [Abstract][Full Text] [Related]
18. Synergism of thrombolytic agents in vivo. Collen D; Stassen JM; Stump DC; Verstraete M Circulation; 1986 Oct; 74(4):838-42. PubMed ID: 3093116 [TBL] [Abstract][Full Text] [Related]
19. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956 [TBL] [Abstract][Full Text] [Related]
20. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K Thromb Haemost; 1991 May; 65(5):560-4. PubMed ID: 1908140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]